Bionor announces three new hires
pharmafile | March 30, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | barbara ruskin, bionor, kamilla rolsted, soren keller
Norwegian biotech Bionor has confirmed that three new members will be joining its executive management team.
Dr Barbara Ruskin, senior vice president, general counsel and chief patent officer, joins Bionor in April and has acted for over two decades advising clients in the biotech and pharma sector.
She has broad experience in patent portfolio management, litigation strategies, corporate transactions and due diligence on behalf of companies and investors. In addition to serving as chief patent officer, Ruskin will oversee all legal affairs for Bionor.
Dr Kamilla Rolsted (pictured), senior VP, chief strategy and business officer also joins the firm in April and has more than 15 years of experience from academia and the pharma industry, most recently at Zealand Pharma where she served as a director of heading strategy and planning. Rolsted will be responsible for strategy and business development at Bionor.
Søren Keller, senior VP, chief operating officer and interim chief financial officer, starts at the Oslo firm with extensive experience as head of operations in both public and private research intensive organisations.
Prior to joining the company Keller served as director and general counsel to the management at Zealand Pharma, and will be responsible for all operations at Bionor. Additionally, Keller will serve as interim CFO.
Dr David Solomon the president and chief executive of the firm says: “I am delighted that Barbara Ruskin, Kamilla Rolsted and Søren Keller have joined Bionor. Together, they bring a wealth of experience to advance therapeutic vaccines for Bionor, and specifically will add operational strength to get our HIV functional cure approach advanced to patients and the markets.”
